VRTX FY 2025 Earnings Report — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

Vertex Pharmaceuticals IncorporatedVRTX

FY 2025 Earnings

Reported February 13, 2026

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2025	Prior Q	FY 2024	QoQ Change	YoY Change
Revenue	$12.1B	—	$11.0B	—	9.6%
Op. Income	$4.8B	—	-$233M	—	2144.1%
Gross Margin	85.0%	—	86.1%	—	-1.1pp
Net Margin	32.7%	—	-4.9%	—	37.6pp
EPS (Diluted)	$15.32	—	$-2.08	—	836.5%
Free Cash Flow	$3.2B	—	-$790M	—	504.1%

Revenue Flow

Item	Amount
REVENUE	$12.1B
Cost of Revenue	$1.8B
GROSS PROFIT	$10.3B
R&D Expenses	$3.8B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$1.8B
Other Expenses	$0
Operating Expenses	$5.5B
Cost & Expenses	$7.3B
OPERATING INCOME	$4.8B
Interest Income	$491M
Interest Expense	$13M
Other Income/Expenses	-$118M
INCOME BEFORE TAX	$4.6B
Income Tax Expense	$690M
Net Income from Continuing Ops	$4.0B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$4.0B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$4.0B
D&A	$207M
EBIT	$4.8B
EBITDA	$5.0B
EPS	$15
EPS Diluted	$15

Income Statement

Item	Amount
REVENUE	$12.1B
Cost of Revenue	$1.8B
GROSS PROFIT	$10.3B
R&D Expenses	$3.8B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$1.8B
Other Expenses	$0
Operating Expenses	$5.5B
Cost & Expenses	$7.3B
OPERATING INCOME	$4.8B
Interest Income	$491M
Interest Expense	$13M
Other Income/Expenses	-$118M
INCOME BEFORE TAX	$4.6B
Income Tax Expense	$690M
Net Income from Continuing Ops	$4.0B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$4.0B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$4.0B
D&A	$207M
EBIT	$4.8B
EBITDA	$5.0B
EPS	$15
EPS Diluted	$15

Cash Flow Statement

Item	Amount
Net Income	$4.0B
Depreciation & Amortization	$207M
Stock-Based Compensation	$0
Deferred Income Tax	-$511M
Other Non-Cash Items	$1.2B
Change in Working Capital	-$1.2B
OPERATING CASH FLOW	$3.6B
Capital Expenditure	-$438M
Acquisitions (Net)	$0
Purchases of Investments	-$6.4B
Sales/Maturities of Investments	$5.9B
Other Investing Activities	-$25M
NET CASH FROM INVESTING	-$945M
Net Debt Issuance	-$5M
Common Stock Repurchased	-$2.0B
Common Dividends Paid	$0
Other Financing Activities	-$366M
NET CASH FROM FINANCING	-$2.3B
FREE CASH FLOW	$3.2B
Net Change in Cash	$516M

Balance Sheet

Item	Amount
Cash & Equivalents	$5.1B
Short-Term Investments	$1.5B
Net Receivables	$2.1B
Inventory	$1.7B
Other Current Assets	$749M
TOTAL CURRENT ASSETS	$11.2B
PP&E (Net)	$3.1B
Goodwill	$1.1B
Intangible Assets	$424M
Long-Term Investments	$5.8B
Tax Assets	$3.4B
Other Non-Current Assets	$1.1B
TOTAL NON-CURRENT ASSETS	$14.9B
TOTAL ASSETS	$26.1B
Account Payables	$462M
Short-Term Debt	$83M
Deferred Revenue	$172M
Other Current Liabilities	$2.7B
TOTAL CURRENT LIABILITIES	$3.9B
Long-Term Debt	$1.8B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$1.3B
Other Non-Current Liabilities	-$1.5B
TOTAL NON-CURRENT LIABILITIES	$3.6B
TOTAL LIABILITIES	$7.5B
Common Stock	$3M
Additional Paid-In Capital	$5.1B
Retained Earnings	$13.6B
Treasury Stock	$0
Accum. Other Comp. Income	-$16M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$18.7B
Minority Interest	$0
TOTAL EQUITY	$18.7B
TOTAL LIABILITIES & EQUITY	$26.1B
Total Debt	$3.9B
Net Debt	-$1.2B